|
eFT508
- 英文名称:eFT508
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11102
- cas:1849590-01-7
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-10-24
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11102 |
| 用途 | 科研检测 |
| 英文名称 | eFT508 |
| 包装规格 | 1MG |
| CAS编号 | 1849590-01-7 |
| 别名 | eFT508 |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C17H20N6O2
分子量:340.39
溶剂:DMSO (2 mg/ml with warming)
性状:Pale yellow solid
存储:-20°C
Activity (short version):Potent MNK1/2 inhibitor
Function / Pharmacology:eFT508 is a potent (IC50s = 2.4 nM MNK1; 1.0 nM MNK2) and highly selective inhibitor of the mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2), key regulators of mRNA translation protein eukaryotic initiation factor eIF4E.1 It potently inhibits phosphorylation of eIF4E in multiple solid and hematological tumor lines leading to blockade of pro-inflammatory and pro-tumorigenic cytokine production. eFT508 reversed the aggressive and metastatic characteristics of mouse liver cancer via inhibition of PD-L1 upregulation.2 Displays inhibitory effects in various cancers models including acute myeloid leukemia3, gastric4, and breast5. eFT-508 has also shown efficacy in treating neuropathic pain via the MNK-eIF4E pathway.6,7,8
分子式:C17H20N6O2
分子量:340.39
溶剂:DMSO (2 mg/ml with warming)
性状:Pale yellow solid
存储:-20°C
Activity (short version):Potent MNK1/2 inhibitor
Function / Pharmacology:eFT508 is a potent (IC50s = 2.4 nM MNK1; 1.0 nM MNK2) and highly selective inhibitor of the mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2), key regulators of mRNA translation protein eukaryotic initiation factor eIF4E.1 It potently inhibits phosphorylation of eIF4E in multiple solid and hematological tumor lines leading to blockade of pro-inflammatory and pro-tumorigenic cytokine production. eFT508 reversed the aggressive and metastatic characteristics of mouse liver cancer via inhibition of PD-L1 upregulation.2 Displays inhibitory effects in various cancers models including acute myeloid leukemia3, gastric4, and breast5. eFT-508 has also shown efficacy in treating neuropathic pain via the MNK-eIF4E pathway.6,7,8



